Fig. 2

Knockdown of astrocytic HDAC7 reduces tau pathology in PS19 mice. A Schematic illustration of AAVs constructed with shRNA targeting the knockdown of HDAC7 or control GFP and the in vivo experimental timeline. B Representative images showing the expression of AAV in the hippocampus of PS19 mice. Scale bar: 200 μm. C, D Representative immunostaining images of GFP and GFAP/ Iba1/NeuN in the hippocampus of 7-month-old PS19 mice, with analysis of the ratio of GFAP⁺ GFP⁺, Iba1⁺ GFP⁺ and NeuN⁺ GFP⁺ double positive cells. n = 7 (PS19-Vec), 8 (PS19-shHD7). Scale bar: 40 μm. E, F Representative immunostaining images with quantification of AT8 in the hippocampus of PS19 mice after AAV injection. n = 7 (PS19-Vec), 8 (PS19-shHD7). Scale bar: 40 μm. G, H Western blotting analysis and quantification of tau accumulation in the supernatant and pellet fraction of hippocampal ex from WT and PS19 mice using AT8, AT100, PHF13 and tau13 antibodies. n = 5 per group. Statistical significance was determined by unpaired Student’s t test. Data are shown as mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, n. s, not significant